Almonertinib after chemoradiation for stage III lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 3 trial tests whether almonertinib given after standard chemoradiation can help people with stage III, non-surgical lung cancer live longer and/or control the cancer. It is for tumors with specific EGFR mutations linked to sensitivity to EGFR-targeted medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to give informed consent
- Have stage III non-small cell lung cancer that cannot be removed with surgery
- Your tumor must have specific EGFR mutations (Ex19Del or L858R) found by an approved EGFR blood/tissue test
- You must have finished standard chemoradiation: at least 2 rounds of platinum chemo and total radiation dose 54–66 Gy, finishing within 6 weeks
- Your cancer must not have grown during or after the chemoradiation (no progression)
- You must have good overall health for trial participation (good energy/strength and enough organ function, and no significant ongoing side effects)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (BL-B01D1 and almonertinib) given before surgery to shrink EGFR-mutated lung cancer. The goal is to make surgery more effective and possibly improve long-term outcomes.
This study tests an oral targeted therapy (firmonertinib) as the first treatment for advanced EGFR-mutated non-small cell lung cancer. It uses blood tests (ctDNA) to see if the drug is working and to guide whether to continue or adjust treatment, aiming to improve outcomes while reducing side effects.
This trial tests a targeted therapy (firmonertinib) combined with standard chemotherapy before surgery, to see if it can shrink tumors and improve outcomes for people with early-stage lung cancer that has a specific EGFR gene change.
This study tests a combination of two targeted therapies for non-small cell lung cancer that has continued to grow despite previous EGFR-targeted treatment. It aims to see if adding gumarontinib (a MET inhibitor) to another EGFR-targeted drug can control the cancer for longer.
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
This study tests whether almonertinib taken after complete surgery can improve outcomes for people with stage II–IIIA non-small cell lung cancer (NSCLC) that has certain EGFR gene changes. It also compares almonertinib plus chemotherapy versus almonertinib alone to see which approach is safer and works better.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.